- Physics - 15:00
Mirrors provide candles for Golden Gate Bridge’s 75th birthday - Business - 14:01
PennMOVES Sale Will Be Held Saturday, June 2 - Arts - 14:00
Martha Roth reappointed to second term as dean of Humanities - Medicine - 13:01
UC San Diego Researchers Receive New CIRM Funding - Business - 12:01
Gains in consumer confidence continue, depend on job growth - History - 11:01
Taiwanese president praises new fellowship fund at University of Michigan - Medicine - 11:00
Insertable Robot Offers New Approach to Minimally Invasive Surgery - Computer Science - 10:00
Is that smile real or fake? - Literature - May 24
UChicago to honor historian Black, theater director Bogart at Convocation - Agronomy - May 24
Diagnostic labs analyze anything from bugs to toenails - Medicine - May 24
UCLA launches first face transplantation program in western U.S - Administration - May 24
’Click It or Ticket’ Enforcement on Penn Campus
By category
Official EventAdministration
Chemistry
Physics
Computer Science
Environmental Sciences
Earth Sciences
Life Sciences
Medicine
Business
Law
Literature
History
Arts
» » more
Researchers pioneer molecular imaging agents to individualize cancer therapy
1 December 2011 - WASHINGTON

A diagnostic image of the brain obtained with positron emission tomography.
“Medical imaging has been used for more than a century and this information has proven invaluable to doctors looking for early-stage occult disease or even looking for the spread of more advanced disease,” said Krohn, co-principal investigator, and a UW professor of radiology and radiation oncology. “The positron emission tomography (PET) agents we have developed are not intended for detection of cancer, but rather for characterization of the disease in an individual patient.”
“Our ability to use PET imaging to identify patients with tumors at high risk for treatment failure, those who are experiencing treatment failure, and those individuals for whom an ideal targeted therapy will have an immediate and direct positive clinical impact,” said Eary, co-principal investigator in the study and a UW professor of nuclear medicine. “Most of the imaging agents we have pioneered are now used around the world and are involved in numerous multi-center clinical trials.”
Other researchers on the project are Jeanne Link, a UW associate professor of nuclear medicine, and David Mankoff, a UW professor of radiology. By showing the chemical reactions actually taking place inside a person’s body, nuclear medicine imaging has the benefit of characterizing the cancer disease within an individual patient. At the very heart of this research project is the collaborative teamwork that takes place between the laboratory scientists and the clinicians.
The UW PET Cancer Group has been actively investigating new imaging agents for more than 20 years. Their work encompasses development of imaging agents, pre-clinical models, and translation to early phase clinical trials. The group consists of radiochemists, clinical imaging specialists, imaging physicists and image analyses experts who interact in a multidisciplinary environment.
The UW PET Cancer Group has been actively investigating new imaging agents for more than 20 years. Their work encompasses development of imaging agents, pre-clinical models, and translation to early phase clinical trials. The group consists of radiochemists, clinical imaging specialists, imaging physicists and image analyses experts who interact in a multidisciplinary environment.
Last job offers
- Law - 21.5
Doctoral Programme at the Law School of the University of Basel - Life Sciences - 18.4
Senior Expert - Genetic Biomarker Oncology (PhD) m/f - Business - 22.5
Research Associate - Civil Engineering - 15.5
Research Specialist - Beckman Institute (A1200274) - Life Sciences - 15.5
Staff Research Associate II - Medicine - 12.5
Research Specialist - Business - 4.5
Assistant Professor of Economics, Non Tenure Track, Fall 2012 - Business - 3.5
Post Doctoral Fellow


» Share this page: